Commentary
Anthocyanins are anti-oxidant plant
pigments credited with wide-ranging therapeutic effects.
Support for the well-accepted role of
anthocyanins in folk medicine the world over has since been confirmed by
epidemiology and, more recently, by an increasing body of science.
Many research trials have demonstrated
anthocyanins' marked ability to inhibit tumour formation and cancer-cell
proliferation. Protection from
cardio-vascular disease and age-related neuro-degenerative disorders have been
clearly shown in scientific studies.
Enter 'genetically-improved' tomatoes,
turned purple by their newly acquired ability to generate anthocyanins and
thereby re-jigged to make everyone healthy.
In fact, the announcement of the first
truly successful GM high-anthocyanin tomato, created by scientists at the John
Innes Centre (JIC) in England came in 2008.
Reported at the same time was that these purple tomatoes had been fed to
GM cancer-prone mice, where they increased life-span by about 30%. A flurry of media coverage in the press,
radio and TV made sure everyone knew that, thanks to GM, tomatoes could now
protect you from cancer, and a stack of other nasty modern conditions.
All this upbeat coverage came from JIC's
own press release which included a quote from the Centre's Professor Cathie
Martin that “The next step will be to take the preclinical data forward to
human studies with volunteers to see if we can promote health through
dietary preventative medicine strategies”.
The answer to cancer was, it seemed, just round the corner.
However, at the same time a (less widely
reported) press release from JIC collaborators at the European Institute of
Oncology warned: “we have not taken into account any possible toxicity so ...
we're far from considering a human trial”.
After some years of silence, the JIC
announced in May 2013 that its unusually-hued GM tomatoes could not only ward
off cancer, but had unexpected additional benefits to growers and all their
customers. Purple tomatoes, it seems,
have a longer shelf-life because their novel anthocyanins confer resistance to
'grey mould', the tomato's most common fungal pest. And not only this, but the GM fruit is better
tasting because it exhibits delayed ripening, allowing the tomatoes to remain
on the vine longer before harvesting.
The time scale to commercial availability
of the GM tomatoes was reportedly 2015 in the US and later in the UK due to the
“unenlightened”, “tougher regulatory process” here.
Again, there was a splurge of media
coverage. The Telegraph reported that a
Canadian firm was growing the GM tomatoes for the JIC researchers who hoped “to
test its health benefits in a clinical trial within the next 12 months”. However, in case this all sounded a bit too
gung-ho-pro-GM for the public stomach, the GM tomatoes were really (apparently)
a tool to allow scientists to “pinpoint exactly how to breed in valuable
traits” and “a new target for breeders”.
Since the genetic transformation involved two look-alike snapdragon
genes, the role of these GM tomatoes in guiding breeding isn't clear.
The arrival of the first shipment of the
2000 litres of GM tomato juice from Canada in January 2014 to be “tested for
its effects on human health” (Independent) put the purple tomato once more
in the media spotlight.
As GM concern groups pointed out, since no
toxicological testing, nor the requisite research on healthy volunteers had
been published, plans to test for therapeutic effects seemed disturbingly
premature.
Also in January, a JIC Facebook post
clearly describes the purpose of the GM juice from Canada as being to generate
“industry collaborations and to start the process of seeking the regulatory
authorisation needed to bring commercial juice to market”. The 'aid to breeding' idea of 2013 seems to
have evaporated in favour of a full-steam ahead GM push to market.
By the end of that month, the JIC seems to
have realised that its own GM hype, which it had allowed the media to
sensationalise without restraint, had become so wildly incorrect that the whole
situation might be about to backfire on its reputation. The Centre, accordingly, posted a “Clarification
on purple tomatoes following media coverage” on Facebook. Its purple GM juice, it seems is for the sole
purpose of initiating further research trials. There are “no plans for any clinical trials
with heart patients”.
The JIC further clarified that the GM juice
is to “help investigate the link between anthocyanin consumption and reductions
in chronic disease risk factors e.g. markers for risk of cancer, cardiovascular
disease and degenerative diseases”.
Wasn't it the proven existence of these very same links to health
benefits that excused the creation of the GM anthocyanin-generating tomatoes in
the first place? Something about
horses and carts springs to mind.
Since toxicology testing of the JIC's GM
tomatoes has not yet reached the starting line, it seems unlikely that Europe's
'unenlightened' regulators are anything to do with the reason the GM tomatoes
will take more than a couple of years to get to market.
SOURCES:
John Innes Centre Facebook Posts 25.01.14 and 31.01.14
Purple tomatoes may keep cancer at bay,
John Innes Centre press release, October 2008
Are Cathie Martin and the JIC throwing medical ethics in the bin? GM Watch 28.01.14
GM Purple Tomatoes Set for EU Legal Problems over Human Testing, Sustainable Pulse 26.01.14
Clive Cookson, Purple tomato juice from Canada for clinical trial in UK, http://sundiatapost.com 25.01.14
Tomatoes, said to be the world's most popular fruit, can be made both better-tasting and longer-lasting thanks to UK research with purple GM varieties, John Innes Centre Press Release 23.05.13
Nick Collins, Genetically modified purple tomato 'tastier than normal varieties', Telegraph 23.05.13
No comments:
Post a Comment
Thanks for your comment. All comments are moderated before they are published.